Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987144 | 0.86 | HDAC1 (0.57) | HDAC1HDAC6CES2CES1TPMT | |
| SCHEMBL30601711 | 0.82 | TPMT (0.54) | HDAC1HDAC6CES2CES1TPMT | |
| SCHEMBL1233792 | 0.82 | TPMT (0.54) | HDAC1HDAC6CES2CES1TPMT | |
| SCHEMBL1233573 | 0.81 | HDAC1 (0.44) | HDAC1HDAC6CES2CES1TPMT | |
| SCHEMBL22468542 | 0.78 | TPMT (0.34) | TPMTALDH1A1 | |
| SCHEMBL22210664 | 0.78 | HDAC1 (0.42) | HDAC1HDAC6CES2CES1TPMT | |
| SCHEMBL524678 | 0.78 | KDM4E (0.48) | HDAC1HDAC6ALDH1A1LMNA | |
| SCHEMBL30601660 | 0.77 | HDAC1 (0.48) | HDAC1HDAC6CES2CES1ALDH1A1 | |
| SCHEMBL26626630 | 0.77 | HDAC1 (0.48) | HDAC1HDAC6CES2CES1ALDH1A1 | |
| SCHEMBL22194152 | 0.75 | NPSR1 (0.44) | HDAC1HDAC6CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| CN-101208301-A | Bicyclic derivatives as p38 kinase inhibitors | PALAU PHARMA SA (ES) | 2008-06-25 | — | — | CN | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | HDAC1 207/4885HDAC6 376/4885CES2 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.